Nafamostat mesylate (formerly also known as FUT-175) is a novel and synthetic serine protease inhibitor, which is used as a short-acting anticoagulant during hemodialysis.

Gabexate Mesylate (Megacert; Arodate) is a novel, potent and synthetic inhibitor of serine protease with anti-coagulant activity.

Alvelestat (formerly also known as MPH966; AZD9668) is a novel, potent, orally bioavailable, and highly selective inhibitor of neutrophil elastase (NE) with potential anti-inflammatory activity.

FOY 251 mesylate is a Camostat metabolite with anti-proteolytic activity, and acts as a proteinase inhibitor.

Fulacimstat (also known as BAY1142524) is a novel, potent and orally bioavailable chymase inhibitor with IC50s of 4, 3 nM for human and hamster chymase enzyme, respectively.

UK-371804 is a potent and selective inhibitor of urokinase-type plasmogen activator (uPA) with excellent potency (Ki=10 nM in an enzyme assay) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin).

Aprotinin is a novel and potent small protein serine protease / bovine pancreatic trypsin inhibitor (BPTI) with antifibrinolytic activity.

AEBSF HCl (known also as AEBSF Hydrochloride) is a novel, broad spectrum, covalently/irreversible inhibitor of serine protease including trypsin, chymotrypsin, plasmin and thrombin.

ZK824190 is an orally available and specific urokinase plasminogen activator (uPA) inhibitor as a highly potential treatment for multiple sclerosis.